HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mulford, D. A. Articles by Jurcic, J. G. Search for Related Content PubMed PubMed Citation Articles by Mulford, D. A. Articles by Jurcic, J. G.

The Promise of Targeted -Particle Therapy

¹ Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
² Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York

The use of monoclonal antibodies to deliver radioisotopes directly to tumor cells has become a promising strategy to enhance the antitumor effects of native antibodies. Since the - and ß-particles emitted during the decay of radioisotopes differ in significant ways, proper selection of isotope and antibody combinations is crucial to making radioimmunotherapy a standard therapeutic modality. Because of the short pathlength (50–80 µm) and high linear energy transfer (100 keV/µm) of -emitting radioisotopes, targeted -particle therapy offers the potential for more specific tumor cell killing with less damage to surrounding normal tissues than ß-emitters. These properties make targeted -particle therapy ideal for the elimination of minimal residual or micrometastatic disease. Radioimmunotherapy using -emitters such as ²¹³Bi, ²¹¹At, and ²²⁵Ac has shown activity in several in vitro and in vivo experimental models. Clinical trials have demonstrated the safety, feasibility, and activity of targeted -particle therapy in the treatment of small-volume and cytoreduced disease. Further advances will require investigation of more potent isotopes, new sources and methods of isotope production, improved chelation techniques, better methods for pharmacokinetic and dosimetric modeling, and new methods of isotope delivery such as pretargeting. Treatment of patients with less-advanced disease and, ultimately, randomized trials comparing targeted -particle therapy with standard approaches will be required to determine the clinical utility of this approach.

Key Words: targeted -particle therapy • radiolabeled monoclonal antibodies • radioimmunotherapy

This article has been cited by other articles:

				G. Sgouros, J. C. Roeske, M. R. McDevitt, S. Palm, B. J. Allen, D. R. Fisher, A. B. Brill, H. Song, R. W. Howell, G. Akabani, et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy J. Nucl. Med., February 1, 2010; 51(2): 311 - 328. [Abstract] [Full Text] [PDF]

				G. Sgouros, R. W. Howell, W. E. Bolch, and D. R. Fisher MIRD Commentary: Proposed Name for a Dosimetry Unit Applicable to Deterministic Biological Effects--The Barendsen (Bd) J. Nucl. Med., March 1, 2009; 50(3): 485 - 487. [Abstract] [Full Text] [PDF]

				M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, T. Z. Wong, and D. D. Bigner Clinical Experience with {alpha}-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 J. Nucl. Med., January 1, 2008; 49(1): 30 - 38. [Abstract] [Full Text] [PDF]

				O. R. Pozzi and M. R. Zalutsky Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 3: {alpha}-Particle-Induced Radiolytic Effects on the Chemical Behavior of 211At J. Nucl. Med., July 1, 2007; 48(7): 1190 - 1196. [Abstract] [Full Text] [PDF]

				M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 PNAS, May 15, 2007; 104(20): 8444 - 8448. [Abstract] [Full Text] [PDF]

				M. R. Zalutsky Targeted {alpha}-Particle Therapy of Microscopic Disease: Providing a Further Rationale for Clinical Investigation J. Nucl. Med., August 1, 2006; 47(8): 1238 - 1240. [Full Text] [PDF]

				G. Glatting, M. Muller, B. Koop, K. Hohl, C. Friesen, B. Neumaier, E. Berrie, P. Bird, G. Hale, N. M. Blumstein, et al. Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia J. Nucl. Med., August 1, 2006; 47(8): 1335 - 1341. [Abstract] [Full Text] [PDF]

				Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 Blood, August 1, 2006; 108(3): 1007 - 1012. [Abstract] [Full Text] [PDF]

				Y. Li, J. Wang, S. M. A. Rizvi, M. J. Jager, R. M. Conway, F. A. Billson, B. J. Allen, and M. C. Madigan In Vitro Targeting of NG2 Antigen by 213Bi-9.2.27 {alpha}-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4365 - 4371. [Abstract] [Full Text] [PDF]